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Abstract
AIM: In our study, we assessed the possibility of using the serum neutrophil gelatinase-associated lipocalin (NGAL) 
for the early detection of kidney damage in patients with acute alcohol poisoning (AAP).
METHODS: The study included 89 patients and 30 healthy donors. All participants in the study were mostly 
represented by men (90%) aged between 20 and 40 years. The influence of alcohol poisoning severity was also 
taken into account in the study. The Human NGAL ELISA Kit was used for the quantitative detection of serum NGAL. 
We also evaluated the main laboratory indicators of kidney functions, including eGFR (calculated according to serum 
creatinine).
RESULTS: We did not find a correlation between blood alcohol concentration and serum NGAL level; also, alcohol 
poisoning severity did not affect the NGAL values. The results of our study showed the possibility of using the serum 
NGAL in patients with AAP to detect the preclinical stage of reduced renal function, until the moment when it can be 
diagnosed with using only serum creatinine.
CONCLUSION: We propose to consider an increase in eGFR together with an increase in serum NGAL in this group 
of patients as a stage, preceding nephropathy, even in the absence of clinical and laboratory signs of impaired renal 
function.
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Introduction
Alcohol use has been identified as a major risk 
factor for disease burden and premature mortality and 
as a global significant problem [1]. Alcohol poisoning is 
constantly recorded in many countries around the world. 
Kazakhstan ranks 34th place from 188 countries in the 
world (10.96 L of alcohol per capita) and first among 
the countries of Central Asia [2]. The overall mortality 
from alcohol poisoning in this region averages 80% [3]. 
The number of alcohol poisoning in Kazakhstan in 2013 
was 86.6 per 100,000 thousand population, and the 
number of alcohol poisoning deaths was 5.6/100,000 
population [2]. Among the acute exogenous poisonings, 
alcohol poisoning is 34.67% and second only to drug 
poisoning – 44.73% [4]. Drinking too much in a short 
period of time may result in a coma and death. One of 
the pathological syndromes in acute alcohol poisoning 
(AAP) is toxic nephropathy – defeat of the glomerular 
apparatus and kidney tissue [5]. The changes are 
due to the direct toxic effect of high concentrations of 
ethanol and acetaldehyde on the renal tissue, as well 
as impaired microcirculation.
The course of nephropathy is prolonged in 
time, irreversible, and progressive. In the preclinical 
stage – there is an accumulation of structural 
changes in the kidney, which could be revealed, until 
sometime, only by puncture biopsy. The first clinical-
stage is characterized by proteinuria, in some cases 
passing into the stage of nephrotic syndrome and, 
as the outcome, the stage of chronic renal failure 
(CRF) [6]. The term “preclinical kidney disease” has 
become widely known since 2006 [7], [8]. It began to 
be used for persons with normal glomerular filtration 
rate (eGFR, according to creatinine level), but with 
elevated serum cystatin C level. It was proposed to 
use cystatin C detection to identify patients at high risk 
of chronic kidney disease (CKD) [7], [9]. For the early 
diagnosis of CKD and detection of renal damage, it 
has also been proposed to use neutrophil gelatinase-
associated lipocalin (NGAL) – specific protein, the level 
of which in blood plasma or urine gradually increases 
during the development of renal dysfunctions [10], [11]. 
NGAL has been shown to be effective in the early 
diagnosis of acute kidney injury (AKI) in various clinical 
settings [12], [13], [14]. The presence of such markers 
opens up the possibility of detection the “preclinical 
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kidney disease,” as well as timely treatment and 
prevention of the disease progression to the CRF 
(corresponding to CKD 3–5 stages). At present, the 
limitations of serum creatinine for the early detection 
and accurate assessment of kidney damage are widely 
known because serum creatinine rises only when the 
function of about 50% of nephrons is lost [15], [16], [17].
The toxicological departments in our country 
most often use the classification of toxic nephropathy 
and its diagnostic criteria proposed by Luzhnikov 
and Kostomarov back in 1989 [18]. At the same time, 
despite the subsequent appearance of improved 
classifications, the decrease in eGFR, progressive with 
increasing the nephropathy severity remains a common 
diagnostic criterion for them. However, as mentioned 
before, the experience of recent years, in particular with 
diabetic nephropathy, shows the “insensitivity” of serum 
creatinine to the early stages of kidney damage and its 
inability to detect the preclinical stage. Late diagnosis 
significantly reduces the effectiveness of treatment 
and, as known, AKI is a strong risk factor for CKD.
Purpose of the study: The purpose of this study 
was to assess the possibility of using the serum NGAL 
for the early detection of kidney damage in patients with 
AAP. In addition, the impact of the alcohol poisoning 
severity and eGFR (calculated according to serum 
creatinine) on the level of NGAL was studied.
Methods
This prospective cross-sectional study was 
conducted on the basis of the biochemical laboratory 
of Karaganda Medical University together with the 
toxicological department of the Regional Medical 
Center (from January 2018 to May 2019). The 
diagnosis of alcohol poisoning and determination of 
the severity of intoxication were carried out according 
to the protocol “The toxic effect of alcohol (adults and 
children)” recommended by the Expert Council of 
the Ministry of Health and Social Development of the 
Republic of Kazakhstan (30.10.2015) with the obligatory 
determination of blood alcohol concentration (BAC). 
The diagnosis confirmation was based on a thorough 
medical history, an objective examination, laboratory 
tests, and determination of BAC. In addition to objective 
data and laboratory tests (AST/ALT ratio and serum 
GGT activity), the CAGE questionnaire was used to 
confirm AAP and exclude chronic alcohol intoxication.
The study included 89 patients with AAP 
and 30 healthy donors (control group). In the study, 
the influence of alcohol poisoning severity (moderate 
degree, n = 42; severe degree, n = 47) was also taken 
into account. All participants in the study were mostly 
represented by men (90%) aged between 20 and 
40 years. Exclusion criteria from the study were as 
follows: Chronic alcohol intoxication, alcoholic or 
viral hepatitis, the presence of acute infectious and 
inflammatory processes of other organs during the study 
period, as well as acute or chronic pyelonephritis of 
infectious etiology, acute or chronic glomerulonephritis, 
diabetes and/or diabetic nephropathy, and obesity. In 
addition, persons younger than 18 years or older than 
40 years were excluded from the study. Blood sampling 
was carried out early in the morning on the 2nd day 
of hospitalization since it is believed that this time is 
enough for a response of serum creatinine in the case of 
AKI [19]. Blood was stabilized by heparin. All blood tests 
were conducted within 2 h after the blood collection. 
The Human NGAL ELISA Kit (Affymetrix eBioscience, 
Austria) was used in the study for the quantitative 
detection of serum NGAL, the unit of measure was pg/
ml. The main laboratory indicators of kidney functions 
were also evaluated. eGFR was calculated according 
to serum creatinine, using the CKD-EPI formula (unit in 
ml/min/1.73 m2). Patients’ BAC averaged 2.2 permille 
(‰, BAC by mass) with a total range of 0.6–4.7 ‰.
Ethical issues
The study was approved by the Ethics 
Committee of Karaganda Medical University and was 
conducted in accordance with the Helsinki Declaration. 
Informed consent from patients and healthy subjects for 
participation was obtained before the study. During the 
presence of patients in the toxicological department, 
all of them received standard therapy, corresponding 
to the poisoning severity and developed complications.
Statistical analysis
The program Statistica for Windows, 
version 12, was used to analyze the received data. One-
way ANOVA for independent variables was used [20] to 
determine significant differences between the groups. 
The choice of this statistical method was due to the 
normal distribution of data (Shapiro–Wilk normality 
test, p > 0.05) and homogeneity of variances (Levene’s 
test, p = 0.591) [21]. The differences were considered 
reliable at significance level p < 0.05. To identify pairs 
of samples, differing from each other in means, we 
used the post hoc Tukey test. In addition, Pearson’s 
correlation analysis was used to estimate correlations 
between the studied parameters.
Results
To study the impact of eGFR on the serum 
NGAL concentration in patients with AAP, we ranked 
conditionally eGFR indexes into three groups: From 
90 to 120 ml/min/1.73 m2 – “normal” eGFR, above 
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120 ml/min/1.73 m2 – “increased” eGFR (from 
121 to 140), and <90 ml/min/1.73 m2 – “reduced” eGFR 
(from 50 to 89). The effect of gender was excluded 
because the study was dominated by men. We found 
that eGFR influenced the level of serum NGAL (F = 4.29, 
p = 0.01) and increased NGAL was observed both at 
“reduced” and “increased” eGFR relative to the control 
group values (p = 0.035 and p = 0.012, respectively).
Next, to analyze the effect of an increase in 
serum NGAL concentration, we added the results of 
laboratory tests of kidney function to the study. We 
divided the patients with AAP into the following groups: 
Group I (n = 25) – with “normal” eGFR without clinical 
and laboratory signs of impaired renal function; Group II 
(n = 20) – with “increased” eGFR without clinical and 
laboratory signs of impaired renal function; and Group III 
(n = 17) – with “normal” or “increased” eGFR and minor 
shifts in urine analysis: Moderate leukocyturia (from 4 
to 14 cells in the field of view) and minor proteinuria 
(0.03–0.1 g/l). And finally, Group IV (n = 27) – patients 
with toxic nephropathy caused by AAP (it corresponds 
to the clinical picture of AKI), confirmed by proteinuria, 
hematuria, leukocyturia, cylindruria, increased serum 
creatinine, as well as reduced eGFR and daily diuresis. 
A control group (individuals without clinical and 
laboratory signs of impaired renal function and without 
signs of AAP) was used as a comparison group.
The level of serum NGAL in the analyzed 
groups is presented in Table 1. Thus, in Group I with 
“normal” eGFR without clinical and laboratory signs of 
impaired renal function, the level of NGAL increased 
slightly, but without a statistically significant difference 
with the control group. In Group II with “increased” 
eGFR, the level of NGAL increased significantly on 
average by 4.5 times compared with the control group 
(p = 0.043). In Groups III and IV, a significant increase 
in the serum NGAL concentration was also detected 
(p = 0.026 and p < 0.001, respectively). The maximum 
values, reaching 1100 pg/ml, were found in Group IV 
patients with toxic nephropathy caused by AAP. The 
level of NGAL in this group exceeded both the values 
of the control group and Group I with “normal” eGFR 
without clinical and laboratory signs of impaired renal 
function (Table 1).
Alcohol poisoning severity, according to our 
data, did not have a statistically significant effect on the 
serum NGAL concentration (F = 0.81, p = 0.37). Hence, 
the level of NGAL was much higher than the values of 
the control group both in moderate degree (m = 527.02; 
CI 95%: 334.06–719.98) and severe degree of alcohol 
poisoning (m = 425.25; CI 95%: 285.31–565.19), 
(p < 0.005). In addition, a correlation analysis showed 
that the NGAL level did not correlate with the BAC, 
while the eGFR correlated with BAC (r = 0.26, p < 0.05) 
and the higher BAC, the higher eGFR.
Discussion
A slight increase in the level of NGAL in 
patients with AAP in the group with “normal” eGFR 
without clinical and laboratory signs of impaired 
renal function is possible, in our opinion, due to the 
direct effect of ethanol on the liver. In addition, all 
patients had leukocytosis with a high percentage of 
segmented neutrophils. It was previously reported that 
the liver and neutrophils are sources of NGAL in the 
blood [12]. In our study, we did not find a correlation 
between BAC and serum NGAL level; also, alcohol 
poisoning severity did not affect the NGAL values. 
The correlation between eGFR and BAC is due to the 
effect of ethanol. The mechanisms of eGFR increasing 
in the case of AAP have been described in detail and 
are associated mainly with hypertonic dehydration and 
an increase in the osmolarity of blood plasma [22]. It 
deserves attention, that the same mechanism, due to 
hyperglycemia, underlies the increase in eGFR in the 
case of diabetic nephropathy.
The results of our study showed that a 
multiple increases in the level of serum NGAL not 
only in patients with nephropathy and reduced eGFR 
but also in patients with “increased” eGFR even in the 
absence of clinical and laboratory signs of impaired 
renal function, as well as in patients with “normal” or 
“increased” eGFR and minor shifts in urine analysis. 
In our opinion, both these groups can be considered 
as patients with a preclinical stage of kidney damage 
and a high risk of nephropathy development. This 
situation is similar to the other, observed in patients with 
diabetes mellitus, in whom, according to the literature, 
microalbuminuria is often accompanied by increased 
eGFR and is considered as the initial stage of diabetic 
nephropathy. It was also shown that the initial stage 
of kidney damage in the case of hypertension is also 
manifested by an increase in eGFR, while at later 
stages – by decline [23]. Thereby, eGFR reflects early, 
intermediate, and later stages of kidney damage, but 
changes in eGFR are not equivalent. The decrease in 
eGFR in combination with the diagnostic criteria of toxic 
nephropathy, proposed by Luzhnikov and Kostomarov, 
reveals only the late stage of kidney damage when the 
function of a significant part of nephrons is lost. Our 
study showed the possibility of using the serum NGAL 
in patients with AAP to detect the preclinical stage of 
reduced renal function, until the moment when it can 
be diagnosed with using only serum creatinine. We 
propose to consider an increase in eGFR together with 
Table 1: Serum NGAL concentration in the analyzed groups
Analyzed groups Mean −95% CI +95% CI
Control group 102.57 42.23 162.91
Group I 219.64 111.83 327.46
Group II 459.15* 290.59* 627.72*
Group III 561.52* 219.48* 903.56*
Group IV 601.02*& 353.58*& 848.45*&
*Reliability of differences with the control group, p<0.05. &Reliability of differences with the Group I, 
p=0.007. CI: Confidence interval.
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an increase in serum NGAL in this group of patients as 
a stage, preceding nephropathy, even in the absence of 
clinical and laboratory signs of impaired renal function. 
Obviously, the changes in the kidneys are reversible 
exactly at the preclinical stage in the case of elimination 
of etiological factor and appropriate therapy. While in 
diagnosed nephropathy, even though the etiological 
factor is eliminated, the renal function worsens 
progressively, and the stage of CRF develops as an 
outcome [6], [24]. However, the main point why and 
due to what mechanisms the changes in the kidneys 
that have arisen initially continue to progress inevitably 
even with the elimination of etiological factor has not yet 
found an exhaustive explanation.
Conclusion
Our study showed the possibility of using the 
serum NGAL in patients with AAP to detect the preclinical 
stage of reduced renal function, until the moment when it 
can be diagnosed with using only serum creatinine. We 
propose to consider an increase in eGFR together with 
an increase in serum NGAL in this group of patients as 
a stage, preceding nephropathy, even in the absence of 
clinical and laboratory signs of impaired renal function.
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